drugset / Trial / NCT07208773

A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors

NCT07208773

Non-randomizedSequentialOpen-labelTreatment

Summary

This study was designed to evaluate the efficacy and safety of YL201 in combination with Ivonescimab (AK112) in subjects with solid tumor.

Timeline

Start
2025-10-29
Primary completion
2027-01
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ivonescimab Monoclonal antibody Intravenous
Subject YL201 Other / unclassified Intravenous